Employees: 1,356
Size Dr. Agarwal'S Eye Hospital (DRAGARWQ.NS) is an India Health Care company (Medical/Nursing Services) with a market value of $292M, the 1066th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹5,834 on 18 Nov 2026.
Performance Over six months the shares gained 14.2%, against -4.0% for the median peer and +3.8% for the India market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 20.0% over the last twelve months (peer median +5.1%); the operating margin is 21.1% (peer median 8.0%).
Valuation It trades at 5.5× enterprise value to sales against a peer median of 1.5× (4th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +27%, so the hurdle is -8 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 11.5 points above its cost of capital (11.1% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹4.97B | ₹4.71B | ₹3.97B | ₹3.19B | ₹2.68B |
| Revenue growth | — | +19% | +24% | +19% | — |
| Gross profit | ₹1.82B | ₹1.61B | ₹1.27B | ₹1.03B | ₹898M |
| EBITDA | ₹1.51B | ₹1.48B | ₹1.21B | ₹931M | ₹766M |
| Net income | ₹762M | ₹701M | ₹546M | ₹464M | ₹369M |
| Free cash flow | n/a | ₹458M | -₹124M | ₹192M | -₹23.0M |
| Capital expenditure | n/a | ₹984M | ₹1.03B | ₹713M | ₹703M |
| Total debt | n/a | ₹3.26B | ₹3.33B | ₹2.68B | ₹2.32B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DRAGARWQ.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +14.9% | -9.6% | 2nd highest of 21 |
| 6-month return | +14.2% | -4.0% | 4th highest of 20 |
| Distance from 52-week high | -5.7% | -30.8% | 2nd highest of 21 |
| Revenue growth (TTM) | +20.0% | +5.1% | 8th highest of 21 |
| Operating margin | 21.1% | 8.0% | 4th highest of 21 |
| EV / Sales | 5.5× | 1.5× | 4th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 19.6% | 5.6% | 2nd most demanding of 17 |
| Growth delivered (Del g) | +27.5% | +15.4% | 4th highest of 17 |
| Hurdle (Req g minus delivered) | -7.9 pp | -13.8 pp | 7th most demanding of 17 |
| ROIC minus cost of capital | +11.5 pp | -2.5 pp | 3rd highest of 20 |
| EV / EBITDA | 18.1× | 8.8× | 2nd most expensive of 13 |
| Net debt / EBITDA | 1.5× | 1.6× | 7th least indebted of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Dr. Agarwal'S Eye Hospital DRAGARWQ.NS | India | $292M | +14% | +20% | 21% | 5.5× | 19.6% | +27.5% |
| Universal Vision Biotechnology 3218.TWO | Taiwan | $309M | -4% | +5% | 31% | 2.4× | -13.8% | +15.4% |
| Auna AUNA | United States | $309M | -5% | +17% | 13% | 1.0× | -10.7% | +24.4% |
| NIOX NIOX.L | United Kingdom | $325M | +3% | +3% | 22% | 4.9× | 3.4% | +15.3% |
| Oncology Institute STLN | United States | $326M | n/a | +35% | -3% | 0.6× | 5.4% | +21.8% |
| Tellgen 300642.SZ | China | $328M | -11% | +5% | 8% | 5.2× | 18.8% | -5.8% |
| Australian Unity Ltd Pref AYUPA.AX | Australia | $352M | +17% | 0% | -2% | 0.4× | -14.9% | +9.6% |
| M1 Kliniken M12.DE | Germany | $368M | +1% | -28% | 13% | 1.2× | -5.3% | +17.9% |
| ADICON 9860.HK | Hong Kong | $393M | +5% | +1% | 4% | 1.3× | 12.3% | -1.5% |
| Jeena Sikho Lifecare JSLL.NS | India | $394M | -55% | +135% | 32% | 4.0× | 7.3% | +42.6% |
| Integral Diagnostics IDX.AX | Australia | $413M | -22% | +26% | 9% | 1.5× | 7.8% | +17.7% |
| Australian Clinical Labs ACL.AX | Australia | $418M | +68% | -1% | 8% | 1.3× | 4.3% | +2.6% |
| Strata Critical Medical SRTA | United States | $443M | -10% | +23% | -4% | 1.4× | n/a | n/a |
| JS Link 127120.KS | South Korea | $458M | -62% | +39% | -83% | 25.2× | n/a | n/a |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $518M | -17% | -19% | 6% | 2.3× | 5.9% | +3.2% |
| Ginkgo Bioworks DNA | United States | $547M | +9% | -44% | -242% | 6.5× | n/a | n/a |
| WELL Health Technologies WELL.TO | Canada | $661M | -9% | +29% | 6% | 1.2× | 10.1% | +94.5% |
| Fulgent Genetics FLGT | United States | $702M | +53% | +5% | -38% | 1.2× | n/a | n/a |
| Nephrocare Health Services NEPHROPLUS.NS | India | $702M | +1% | +33% | 13% | 5.6× | 36.6% | +31.6% |
| GMR Solutions GMRS | United States | $714M | -8% | -4% | 14% | 0.9× | -19.6% | -4.0% |
| Jinxin Fertility 1951.HK | Hong Kong | $758M | -4% | +7% | 11% | 2.8× | 17.8% | +12.4% |